NCT05022862 Economic Incentives and vDOT for Latent Tuberculosis Infection
| NCT ID | NCT05022862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Latent Tuberculosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 399 participants |
| Start Date | 2022-02-07 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 399 participants in total. It began in 2022-02-07 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.
Eligibility Criteria
Inclusion Criteria: * 18 years old or older, * diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians * reside in Baltimore metro area * speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board * prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin Exclusion Criteria: * younger than 18 years old * diagnosed with active TB * prescribed an alternative treatment regimen for latent TB * pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated) * participant's spoken language does not have a translated long or short consent form
Contact & Investigator
Maunank Shah, MD, PhD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT05022862 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Latent Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05022862 currently recruiting?
Yes, NCT05022862 is actively recruiting participants. Contact the research team at mshah28@jhmi.edu for enrollment information.
Where is the NCT05022862 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT05022862 clinical trial?
NCT05022862 is sponsored by Johns Hopkins University. The principal investigator is Maunank Shah, MD, PhD at Johns Hopkins University. The trial plans to enroll 399 participants.